Bellicum investor alert: faruqi & faruqi, llp encourages investors who suffered losses exceeding $50,000 investing in bellicum pharmaceuticals, inc. to contact the firm

New york--(business wire)--faruqi & faruqi, llp, a leading national securities law firm, is investigating potential claims against bellicum pharmaceuticals, inc. (“bellicum” or the “company”) (nasdaq:blcm). aftermarket on january 30, 2018, bellicum issued a press release entitled “bellicum pharmaceuticals announces clinical hold on bpx-501 clinical trials in the united states[.]” therein, the company announced that it had “received notice from the u.s. food and drug administration (fda) that u.s. studies of bpx-501 have been placed on a clinical hold following three cases of encephalopathy deemed as possibly related to bpx-501.” bpx-501 is the company’s lead clinical product candidate designed to improve outcomes for patients undergoing stem cell transplant who lack a matched donor. on this news, the company’s share price fell from $8.20 per share on january 30, 2018 to a closing price of $6.08 on january 31, 2018—a $2.12 or a 25.85% drop. if you invested in bellicum stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/blcm. there is no cost or obligation to you. you can also contact us by calling richard gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. attorney advertising. the law firm responsible for this advertisement is faruqi & faruqi, llp (www.faruqilaw.com). prior results do not guarantee or predict a similar outcome with respect to any future matter. we welcome the opportunity to discuss your particular case. all communications will be treated in a confidential manner.
BLCM Ratings Summary
BLCM Quant Ranking